share_log

It's Down 29% But Acutus Medical, Inc. (NASDAQ:AFIB) Could Be Riskier Than It Looks

It's Down 29% But Acutus Medical, Inc. (NASDAQ:AFIB) Could Be Riskier Than It Looks

下跌了29%,但Acutus Medical, Inc.(纳斯达克股票代码:AFIB)的风险可能比看起来更大
Simply Wall St ·  02/24 07:23

Acutus Medical, Inc. (NASDAQ:AFIB) shareholders won't be pleased to see that the share price has had a very rough month, dropping 29% and undoing the prior period's positive performance.    The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 85% loss during that time.  

Acutus Medical, Inc.(纳斯达克股票代码:AFIB)股东们不会很高兴看到股价经历了一个非常艰难的月份,下跌了29%,抵消了前一时期的积极表现。对于股东来说,最近的下跌结束了灾难性的十二个月,在此期间,股东亏损了85%。

After such a large drop in price, Acutus Medical may look like a strong buying opportunity at present with its price-to-sales (or "P/S") ratio of 0.3x, considering almost half of all companies in the Medical Equipment industry in the United States have P/S ratios greater than 3.6x and even P/S higher than 8x aren't out of the ordinary.   However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.  

在价格大幅下跌之后,Acutus Medical目前看上去是一个强劲的买入机会,其市销率(或 “市盈率”)为0.3倍,因为美国医疗设备行业几乎有一半公司的市销率大于3.6倍,即使市盈率高于8倍也并非不寻常。但是,市销率可能很低是有原因的,需要进一步调查以确定其是否合理。

NasdaqCM:AFIB Price to Sales Ratio vs Industry February 24th 2024

纳斯达克股票代码:AFIB与行业的股价销售比率 2024年2月24日

What Does Acutus Medical's Recent Performance Look Like?

Acutus Medical 最近的表现是什么样子?

Acutus Medical has been doing a good job lately as it's been growing revenue at a solid pace.   It might be that many expect the respectable revenue performance to degrade substantially, which has repressed the P/S.  Those who are bullish on Acutus Medical will be hoping that this isn't the case, so that they can pick up the stock at a lower valuation.    

Acutus Medical最近表现不错,收入一直在稳步增长。可能是许多人预计可观的收入表现将大幅下降,这抑制了市销率。那些看好Acutus Medical的人会希望情况并非如此,这样他们就可以以较低的估值买入该股。

Want the full picture on earnings, revenue and cash flow for the company? Then our free report on Acutus Medical will help you shine a light on its historical performance.  

想全面了解公司的收益、收入和现金流吗?那么我们关于Acutus Medical的免费报告将帮助您了解其历史表现。

Is There Any Revenue Growth Forecasted For Acutus Medical?  

预计Acutus Medical的收入会增长吗?

Acutus Medical's P/S ratio would be typical for a company that's expected to deliver very poor growth or even falling revenue, and importantly, perform much worse than the industry.  

Acutus Medical的市销率对于一家预计增长非常糟糕甚至收入下降的公司来说是典型的,而且重要的是,其表现要比行业差得多。

Retrospectively, the last year delivered an exceptional 25% gain to the company's top line.   The strong recent performance means it was also able to grow revenue by 200% in total over the last three years.  Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.  

回顾过去,去年的公司收入实现了25%的惊人增长。最近的强劲表现意味着它在过去三年中总收入增长了200%。因此,股东们肯定会对这些中期收入增长率表示欢迎。

Comparing that to the industry, which is only predicted to deliver 8.5% growth in the next 12 months, the company's momentum is stronger based on recent medium-term annualised revenue results.

相比之下,该行业预计在未来12个月内仅实现8.5%的增长,根据最近的中期年化收入业绩,该公司的势头更强劲。

With this in mind, we find it intriguing that Acutus Medical's P/S isn't as high compared to that of its industry peers.  It looks like most investors are not convinced the company can maintain its recent growth rates.  

考虑到这一点,我们发现有趣的是,Acutus Medical的市销率与业内同行相比没有那么高。看来大多数投资者不相信该公司能够维持其最近的增长率。

The Bottom Line On Acutus Medical's P/S

Acutus Medical 市销率的底线

Having almost fallen off a cliff, Acutus Medical's share price has pulled its P/S way down as well.      Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

在差点跌下悬崖之后,Acutus Medical的股价也大幅下调了市销率。通常,在做出投资决策时,我们谨慎行事,不要过多地考虑市售比率,尽管这可以揭示其他市场参与者对公司的看法。

We're very surprised to see Acutus Medical currently trading on a much lower than expected P/S since its recent three-year growth is higher than the wider industry forecast.  When we see robust revenue growth that outpaces the industry, we presume that there are notable underlying risks to the company's future performance, which is exerting downward pressure on the P/S ratio.  While recent revenue trends over the past medium-term suggest that the risk of a price decline is low, investors appear to perceive a likelihood of revenue fluctuations in the future.    

我们非常惊讶地看到,Acutus Medical目前的市销率远低于预期,因为其最近三年的增长高于整个行业的预期。当我们看到强劲的收入增长超过该行业时,我们认为公司的未来业绩存在明显的潜在风险,这给市销率带来了下行压力。尽管过去中期最近的收入趋势表明价格下跌的风险很低,但投资者似乎认为未来收入可能会出现波动。

And what about other risks? Every company has them, and we've spotted   4 warning signs for Acutus Medical  (of which 3 are potentially serious!) you should know about.  

那其他风险呢?每家公司都有警告,我们已经发现了Acutus Medical的4个警告信号(其中3个可能很严重!)你应该知道。

It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).

重要的是要确保你寻找一家优秀的公司,而不仅仅是你遇到的第一个想法。因此,如果盈利能力的增长与你对一家优秀公司的想法一致,那就来看看这份免费名单吧,列出了最近收益增长强劲(市盈率低)的有趣公司。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发